2022-11-11-深交所-华东医药_2022年第三季度报告（英文版）_20页_556kb

Huadong Medicine Co., Ltd. - Third Quarterly Report 2022 Summary

Financial Performance

• Operating income for Q3 2022 was RMB 9.66 billion, a 10.43% increase year-over-year, following a 7.4% growth in the first nine months.
• Net profit attributable to shareholders after non-recurring items was RMB 629 million, up 10.77% year-over-year, with a 7.9% increase for the first nine months.
• Key metrics showed strong recovery amid market challenges, including a 11.39% return on equity (ROE) for the first nine months.

Business Segments

• Pharmaceutical segment (including CSO and industrial microbiology) saw moderate growth but faced delays due to international demand shifts; expected recovery in Q4.
• Aesthetic medicine segment recorded high operational growth, with international expansion, particularly in Ellansé® sales in China, contributing to record quarterly results.
• Overall operations stabilized, with steady growth in key areas despite external pressures.

Key Developments and Investments

• R&D progress includes advancements in GLP-1 receptor agonists, ADC drugs, and biosimilars, with several Phase I and II clinical trials completed or ongoing.
• Strategic equity investments in Heidelberg Pharma AG and Huaren Science and Technology strengthened positions in oncology and nucleoside raw materials.
• Future-oriented initiatives include collaborations in synthetic biology and an equity incentive plan to retain talent.

Shareholder Information

• Total common shareholders: 83,815.
• Top shareholders: China Grand Enterprises Inc. (41.77% stake), Hangzhou Huadong Medicine Group Co., Ltd. (16.46%), and other significant entities.
• No changes in voting rights or major stakeholder relations reported.

Forward Outlook

• Company anticipates continued growth across segments, with a focus on innovation and international market penetration.
• Equity incentive plan approved to align employee interests with long-term company goals.